References
1. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. N Engl J Med 2009; 360: 2277-88.
2. Bennett C, Moayyedi P, Corley DA, et al. BOB CAT Consistorium: A Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol 2015; 110: 662-82.
3. National Institute for Health and Care Excellence. Endoscopic radiofrequency ablation for Barrett's oesophagus with low-grade dysplasia or no dysplasia. 2014. Available from: https://www.nice.org.uk/guidance. Accessed 2016 May 30.
4. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68: 867-76.
5. Rees JR, Lao-Sirieix P, Wong A, et al. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010; (1): CD004060.
6. Tham T. Guidelines on the Diagnosis and Management of Barrett's Oesophagus - An Update. London: British Society of Gastroenterology 2015. Available from: http://www.bsg.org.uk/. Accessed 2016 Jun 16.
7. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology 2011; 140: e18-52.
8. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-83.
9. Sikkema M, de Jonge PJF, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8: 235-44.
10. Bennett C, Vakil N, Bergman J, et al. Consensus Statements for Management of Barrett’s Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. Gastroenterology 2012; 143: 336-46.
11. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus (BSG). Gut 2014; 63: 7-42.
12. Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49 (2 Supl. 1-4): 191-8.
13. Darbà J, Kaskens L, Plans P, et al. Epidemiology and societal costs of gastroesophageal reflux disease and Barrett’s syndrome in Germany, Italy and Spain. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 225-32.
14. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-17.
15. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010; 42: 781-9.
16. López Bastida J, Oliva J, Antoñanzas F, et al. [A proposed guideline for economic evaluation of health technologies]. Gac Sanit 2010; 24(2): 154-70.
17. National Statistics Institute. Life tables for the population of Spain by Year, Sex, Age and Function, 2014. Series 1975-2014. Available from: http://www.ine.es/en/. Accessed 2016 June 23.
18. Spanish Health Costs Database: eSalud. Barcelona: Oblikue Consulting, S.L. 2007. Available from: http://www.oblikue.com/bddcostes/. Accessed 2016 Jun 17.
19. General Council of the Association of Official Pharmacists. General Council of the Association of Official Pharmacists Database: Bot PLUS 2.0. Available from: https://botplusweb.portalfarma.com/. Accessed 2016 Jun 16.
20. Gerson LB. Cost-Analyses Studies in Barrett's Esophagus: What Is Their Utility? Gastroenterol Clin North Am 2015; 44: 425-38.
21. National Statistics Institute. National Health Survey. 2013. Available from: http://www.ine.es/en. Accessed 2016 Jun 17.
22. Sacristán JA, Oliva J, Del Llano J, et al. [What is an efficient health technology in Spain?]. Gac Sanit 2002; 16: 334-43.
23. Inadomi JM. Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. Best Pract Res Clin Gastroenterol 2015; 29: 51-63.
24. Gerson LB, Ullah N, Hastie T, et al. Does cancer risk affect health-related quality of life in patients with Barrett's esophagus? Gastrointest Endosc 2007; 65: 16-25.
25. National Institute for Health and Care Excellence. Epithelial radiofrequency ablation for Barrett's oesophagus. London: 2010. Available from: https://www.nice.org.uk/guidance/ipg344 Accessed 2016 Jun 13.
26. Centre for Clinical Practice at NICE. Barrett’s Oesophagus: Ablative Therapy for the Treatment of Barrett’s Oesophagus. Appendix 6, Cost effectiveness analysis for Barrett’s oesophagus. London: National Institute for Health and Clinical Excellence; 2010. Available from: http://www.ncbi.nlm.nih.gov/books/. Accessed 2016 Jul 1.
27. Hur C, Choi SE, Rubenstein JH, et al. The Cost-Effectiveness of Radiofrequency Ablation for Barrett’s Esophagus. Gastroenterology 2012; 143: 567-75.
28. Boger PC, Turner D, Roderick P, et al. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther 2010; 32: 1332-42.
29. Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009; 136: 2101-14.
30. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1245-55.
31. Komeda Y, Bruno M, Koch A. EMR is not inferior to ESD for early Barrett’s and EGJ neoplasia: An extensive review on outcome, recurrence and complication rates. Endosc Int Open 2014; 2: 58-64.
32. Sánchez MC, Fernández L, Atienza G. [Radiofrequency ablation for Barrett´s esophagus with high-grade dysplasia or intramucosal cancer: a systematic review]. Informes de evaluación de tecnologías sanitarias; 2015. Available from: http://avalia-t.sergas.es/DXerais/305/avalia-t201502_RadiofrecuenciaBarret_DEF.pdf. Accessed 2016 Jun 23.
33. Phoa KN, Rosmolen WD, Weusten BL, et al. The cost-effectiveness of radiofrequency ablation for Barrett's Esophagus with low-grade dysplasia: Results from a randomized controlled trial (SURF-trial). Gastrointest Endosc 2017; 86(1):120-29.
34. Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol 2016; 111(1): 30-50.
35. Martín de Argila de Prados C, Aguilera Castro L, Rodríguez de Santiago E. PPIs: between overuse and underprescription when really necessary. Rev Esp Enferm Dig 2015; 107(11): 649-51.
36. Aguilera-Castro L, Martín-de-Argila-dePrados C, Albillos-Martínez A. Practical considerations in the management of proton-pump inhibitors. Rev Esp Enferm Dig 2016; 108(3):145-53.
37. Hu Y, Puri V, Shami VM, et al. Comparative Effectiveness of Esophagectomy Versus Endoscopic Treatment for Esophageal High-grade Dysplasia. Ann Surg 2016; 263: 719-26.